you are here:

Jubilant Pharmova Ltd.

BSE: 530019 | NSE: JUBLPHARMA |

Represents Equity.Intra - day transactions are permissible and normal trading is done in this category
Series: EQ | ISIN: INE700A01033 | SECTOR: Pharmaceuticals

BSE Live

Jun 21, 16:00
746.70 12.10 (1.65%)
Volume
AVERAGE VOLUME
5-Day
36,415
10-Day
41,642
30-Day
32,393
35,870
  • Prev. Close

    734.60

  • Open Price

    729.00

  • Bid Price (Qty.)

    746.70 (112)

  • Offer Price (Qty.)

    746.70 (1)

NSE Live

Jun 21, 15:55
747.25 13.55 (1.85%)
Volume
AVERAGE VOLUME
5-Day
354,214
10-Day
375,674
30-Day
382,907
415,682
  • Prev. Close

    733.70

  • Open Price

    730.00

  • Bid Price (Qty.)

    0.00 (0)

  • Offer Price (Qty.)

    747.25 (424)

ANNOUNCEMENTS ON Jubilant Pharmo

  • Jun 18, 2021 13:33 Source: BSE

    Jubilant Pharmova - Announcement under Regulation 30 (LODR)-Investor Presentation

    In continuation of our letter dated June 10, 2021, we enclose presentation to be made at Investor and Analyst Meet on June 18, 2021.

  • Jun 15, 2021 19:08 Source: BSE

    Jubilant Pharmova - Intimation Pursuant To Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015,

    Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose a communication pertaining to manufacturing partnership for US production of COVID-19 Vaccine candidate, COVAXIN® by Jubilant HollisterStier LLC, a step down subsidiary of the Company.

  • Jun 11, 2021 18:34 Source: BSE

    Jubilant Pharmova - Compliances-Reg.24(A)-Annual Secretarial Compliance

    Pursuant to the SEBI Circular no. CIR/CFD/CMD1/27/2019 dated February 8, 2019, please find enclosed the Annual Secretarial Compliance Report dated June 4, 2021 for the financial year 2020-21.

  • Jun 10, 2021 9:46 Source: BSE

    Jubilant Pharmova - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Company is organising Investor and Analyst Meet on June 18, 2021. Details of the same are attached. This is for information and record.

  • Jun 07, 2021 16:45 Source: BSE

    Jubilant Pharmova - Announcement under Regulation 30 (LODR)-Newspaper Publication

    In continuation of our letter dated June 4, 2021, we enclose copies of the Audited Consolidated Financial Results for the quarter and year ended March 31, 2021 published on June 5, 2021 in MINT (English) and HINDUSTAN (Hindi).

  • Jun 04, 2021 16:34 Source: BSE

    Jubilant Pharmova - Announcement under Regulation 30 (LODR)-Dividend Updates

    Pursuant to the provisions of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company has, at its meeting held today i.e. on June 4, 2021, recommended a dividend of Rs. 5 (Rupees five only) per equity share of Re.1 each for the year ended March 31, 2021. The dividend, if approved by the shareholders at the ensuing Annual General Meeting of the Company, will be paid / despatched on or before October 20, 2021. We request you to take the same on record.

  • Jun 04, 2021 16:31 Source: BSE

    Jubilant Pharmova - Results For The Quarter And Year Ended March 31, 2021

    In terms of Regulation 33 read with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the 'Listing Regulations'), we wish to inform you that the Audited Financial Results (Standalone and Consolidated) of the Company for the quarter and year ended March 31, 2021 were approved by the Board of Directors of the Company at its meeting held today at 1:35 p.m. and concluded at 4.20 p.m. Pursuant to the applicable provisions of the Listing Regulations, we enclose the following: 1. The Audited Financial Results (Standalone and Consolidated) for the quarter and year ended March 31, 2021; 2. Audit Reports for Standalone and Consolidated Financial Results; 3. Copies of the Press Release and Presentation. We declare that the Reports of Auditors are with unmodified opinion with respect to the Audited Financial Results (Standalone and Consolidated) of the Company for the quarter and year ended March 31, 2021.

  • May 28, 2021 18:19 Source: BSE

    Jubilant Pharmova - Schedule Of Investor Conference Call For Jubilant Pharmova Limited - Audited Financial Results For The Year Ended March 31, 2021

    Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Company is organising a Conference Call on June 4, 2021 after submission of the financial results for the quarter and year ended March 31, 2021 to the Stock Exchanges. Details of the Conference Call are attached.

  • May 28, 2021 15:49 Source: BSE

    Jubilant Pharmova - Board Meeting Intimation for 1. Audited Standalone And Consolidated Financial Results Of The Company For The Quarter And Year Ended March 31, 2021; And
    2. Recommendation Of Dividend For The Financial Year Ended March 31, 2021.

    Jubilant Pharmova Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/06/2021 ,inter alia, to consider and approve In terms of Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the 'Listing Regulations'), we wish to inform you that a meeting of the Board of Directors of the Company is scheduled to be held on Friday, June 4, 2021, to inter-alia consider: 1. Audited Standalone and Consolidated Financial Results of the Company for the quarter and year ended March 31, 2021; and 2. Recommendation of Dividend for the Financial Year ended March 31, 2021.

  • May 27, 2021 18:02 Source: BSE

    Jubilant Pharmova - Announcement under Regulation 30 (LODR)-Credit Rating

    Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that India Ratings and Research has upgraded Long Term Issuer Rating to 'IND AA+' from 'IND AA' while resolving the Rating Watch Evolving (RWE) and has simultaneously withdrawn it. The Outlook is stable.

CORPORATE ANNOUNCEMENTS

BOARD MEETING

Meeting Date : Jun 04, 2021
Remark : Audited Results & Final Dividend